Opyn Health, a leader in price transparency, virtual care, and provider directory services, has acquired Empara, an innovative AI-powered benefits engagement and administration platform. This acquisition supports their shared goal of simplifying healthcare by integrating Empara’s advanced AI platform and user-friendly member app with Opyn’s extensive product offerings and data capabilities.
Health Technology Insights: Prolink Names Vanessa Janus Chief Workforce Solutions Officer
Richard Fuchs, CEO and board chair of Opyn, highlighted the challenges in the self-funded insurance market, where outdated systems and numerous confusing portals create inefficiencies. He emphasized that merging Opyn’s member-focused solutions with Empara’s intelligent platform will create a single, easy-to-use access point for healthcare that saves time and money for members, plans, and administrators alike.
The unified platform aims to deliver a seamless experience for members by consolidating all healthcare tools into one AI-driven interface. For administrators, the integration promises more scalable and efficient operations, reducing manual processes and improving service quality, which can lead to sustainable profitability over time.
Health Technology Insights: Pelage Pharmaceuticals Raises $120 Million Series B to Boost Hair Loss Treatments
Markus Waite, President of Empara, expressed enthusiasm about the acquisition, saying that joining forces with Opyn enables them to create a more connected healthcare experience. He pointed out that their collaboration will empower individuals to better manage their benefits, replacing complexity with clarity, accessibility, and trust.
The combined services will be available to third-party administrators, brokers, self-insured employers, professional employer organizations, MEC plans, and other alternative healthcare providers. Empara was originally developed within the Goodroot community, which supports startups focused on affordable and accessible healthcare. Empara’s founders—Markus Waite, Ben Callaghan, and Mike Nigels—will join Opyn Health to further enhance AI capabilities by leveraging Opyn’s rich pricing data and digital health services.
Health Technology Insights: Micro Interventional Devices Gets FDA Nod for STTAR-US Trial
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
